Trispecific antibody targeting CD79b, CD20, and CD3

US12103977B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Rajkumar Ganesan · Blue Bell, US
• Anna Kuchnio · Edegem, BE
• Cassandra L. Lowenstein · Ambler, US
• Ulrike PHILIPPAR · Ekeren, BE
• Sanjaya Singh · Sandy Hook, US
• Nele Vloemans · Oostmalle, BE
• Danlin Yang · Philadelphia, US

Key dates

• Filing date: Mar 23, 2022
• Grant date: Oct 1, 2024
• Expiry date: Mar 23, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and us…